Department of Surgery, Post Graduation Program in Digestive Surgery, Hospital de Clínicas de Porto Alegre, Rua Santa Cecília 1373/316 Bairro Santana, CEP 90420-041, Porto Alegre, RS, Brazil.
Dig Dis Sci. 2013 Jan;58(1):115-22. doi: 10.1007/s10620-012-2316-z. Epub 2012 Aug 9.
Gastroesophageal reflux disease (GERD) is a pathology with a wide range of clinical and endoscopic manifestations. Epidermal growth factor receptor (EGFR), found in the epithelium of the digestive tract, plays an important role in epithelial repair and shows increased expression in different neoplasms, including esophageal tumors.
The purpose of this study was to evaluate EGFR expression using immunohistochemistry in esophageal biopsies obtained from patients with GERD, Barrett's esophagus, and adenocarcinoma of the esophagus.
EGFR expression was immunohistochemically determined in biopsies from 194 patients with symptoms suggestive of GERD or adenocarcinoma of the esophagus, seen at two Brazilian university hospitals between January 2003 and December 2008. Based on histopathological analysis, patients were divided into three groups: GERD, Barrett's esophagus and adenocarcinoma of the esophagus. EGFR expression was considered positive when staining was detected in the membrane.
Mean age was 55.25 years (range 30-90). Patients with GERD (n = 127) accounted for 65.5% of the sample, compared with 12.4% (n = 24) of patients with Barrett's esophagus and 22.2% (n = 43) of patients with esophageal adenocarcinoma. Immunohistochemical analysis was positive for EGFR in 19.1% of the patients (37/194), divided as follows: 8.7% (11/127) in the GERD group, 25% (6/24) in the Barrett's esophagus group, and 46.5% (20/43) in the esophageal adenocarcinoma group. Statistical analysis revealed significant differences between the three groups (p = 0.0001).
GERD patients showed lower levels of EGFR expression than patients with Barrett's esophagus or patients with adenocarcinoma of the esophagus, suggesting a direct relationship between EGFR expression and disease progression.
胃食管反流病（GERD）是一种临床表现和内镜表现广泛的疾病。表皮生长因子受体（EGFR）存在于消化道上皮中，在上皮修复中发挥重要作用，并在包括食管肿瘤在内的不同肿瘤中表达增加。
本研究旨在通过免疫组织化学方法评估 GERD、巴雷特食管和食管腺癌患者食管活检中 EGFR 的表达。
对 2003 年 1 月至 2008 年 12 月期间在巴西两所大学医院就诊的有 GERD 或食管腺癌症状的 194 例患者的活检标本进行 EGFR 表达的免疫组织化学检测。根据组织病理学分析，患者分为三组：GERD、巴雷特食管和食管腺癌。当膜上检测到染色时，认为 EGFR 表达为阳性。
平均年龄为 55.25 岁（范围 30-90）。GERD 患者（n=127）占样本的 65.5%，巴雷特食管患者（n=24）占 12.4%，食管腺癌患者（n=43）占 22.2%。免疫组织化学分析显示 19.1%的患者（37/194）EGFR 阳性，分为：GERD 组 8.7%（11/127），巴雷特食管组 25%（6/24），食管腺癌组 46.5%（20/43）。三组间差异有统计学意义（p=0.0001）。
与巴雷特食管或食管腺癌患者相比，GERD 患者的 EGFR 表达水平较低，提示 EGFR 表达与疾病进展直接相关。
